Verve Therapeutics, Inc. (VERV) has disclosed a new risk, in the Innovation / R&D category.
Verve Therapeutics, Inc. faces a significant business risk regarding its intellectual property, particularly due to ongoing patent interference proceedings with the Boston Licensing Parties, CVC, Toolgen, Inc., and Sigma-Aldrich Co., LLC. These disputes, which determine the priority of invention claims, could result in Verve losing the ability to license crucial CRISPR-Cas9 gene-editing technology. If the company cannot secure necessary licenses or if patents are invalidated, Verve’s capacity to commercialize its product candidates could be compromised, potentially causing material adverse impacts on its business operations and financial prospects.
Overall, Wall Street has a Strong Buy consensus rating on VERV stock based on 6 Buys and 1 Hold.
To learn more about Verve Therapeutics, Inc.’s risk factors, click here.
